For the quarter ending 2026-03-31, RANI made $1,708,000 in revenue. -$7,033,000 in net income. Net profit margin of -411.77%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Contract revenue | 1,708,000 | 1,461,000 | 0 | 0 |
| Research and development | 5,161,000 | 4,909,000 | 3,221,000 | 5,505,000 |
| General and administrative | 4,886,000 | 5,087,000 | 4,036,000 | 5,000,000 |
| Impairment loss | - | 0 | - | - |
| Total operating expenses | 10,047,000 | 9,996,000 | 7,257,000 | 10,505,000 |
| Loss from operations | -8,339,000 | -8,535,000 | -7,257,000 | -10,505,000 |
| Interest income and other, net | 412,000 | 383,000 | 68,000 | 158,000 |
| Interest expense and other, net | 88,000 | 346,000 | 725,000 | 877,000 |
| Loss on extinguishment of debt | - | -576,000 | - | - |
| Net loss | -8,015,000 | -9,074,000 | -7,914,000 | -11,224,000 |
| Net gain attributable to non-controlling interest | -982,000 | 1,231,000 | -2,502,000 | -4,532,000 |
| Net loss attributable to rani therapeutics holdings, inc | -7,033,000 | -10,305,000 | -5,412,000 | -6,692,000 |
| Basic EPS | -0.04 | 0.089 | -0.12 | -0.18 |
| Diluted EPS | -0.04 | 0.089 | -0.12 | -0.18 |
| Basic Average Shares | 179,996,000 | -116,161,448 | 46,444,000 | 36,542,000 |
| Diluted Average Shares | 179,996,000 | -116,161,448 | 46,444,000 | 36,542,000 |
Rani Therapeutics Holdings, Inc. (RANI)
Rani Therapeutics Holdings, Inc. (RANI)